Avoro Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Avoro Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-219,500	Closed	-$10.1M	–	46
2017 Q2	$10.1M	Buy	+219,500	New	+$10.6M	1.27%	23
2017 Q1	–	Sell	-541,000	Closed	-$20.9M	–	49
2016 Q4	$20.9M	Buy	541,000 +50,418	+10%	+$2.28M	4.23%	10
2016 Q3	$24.8M	Sell	490,582 -18,748	-4%	-$934K	4.36%	9
2016 Q2	$23.1M	Buy	509,330 +104,010	+26%	+$4.79M	5.14%	7
2016 Q1	$16M	Buy	405,320 +278,320	+219%	+$11M	5.59%	6
2015 Q4	$7.18M	Buy	+127,000	New	+$6.45M	2.47%	16

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors's NBIX Position: Q3 2017 in Review

Avoro Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 219,500 shares — an estimated $10.1M sold.

Avoro Capital Advisors first reported a position in NBIX in Q4 2015 and held it in 6 quarters. The position peaked at $24.8M in Q3 2016. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

Avoro Capital Advisors reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
Avoro Capital Advisors sold 219,500 Neurocrine Biosciences shares in Q3 2017, an estimated $10.1M.
Avoro Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 6 quarters.
Avoro Capital Advisors's Neurocrine Biosciences position peaked at $24.8M in Q3 2016.
223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Avoro Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.